Printer Friendly



IQ Revenues: $10.9 billion (-4%)

IQ Earnings: $2.4 billion (+2%)

Comments: Established product sales were down 10% to $5.0 billion in the quarter, primarily due to the loss of exclusivity for Celebrex in the U.S., as well as generic competition for Zyvox IV in the U.S., and for Lyrica in certain developed European markets. These declines were partially offset by performance in emerging markets, where revenues increased 10% operationally, primarily driven by Lipitor, Viagra and Norvasc. GlobalVaccine sales were up 44% to $1.3 billion. Consumer Healthcare sales were up 6% to $808 million. Global Oncology sales were $528 million up 8%. R&D Expenses were up 16% to $1.9 billion.

COPYRIGHT 2015 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Quarterly Reports
Publication:Contract Pharma
Date:Jun 1, 2015
Previous Article:Gilead's Harvoni drives growth but offsets Sovaldi sales.
Next Article:Merck.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters